About us Contacts Drug interactions: 390 212
Drug search by name

Dofetilide and Verelan PM

Determining the interaction of Dofetilide and Verelan PM and the possibility of their joint administration.

Check result:
Dofetilide <> Verelan PM
Relevance: 14.07.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Using dofetilide together with verapamil is not recommended. Combining these medications may significantly increase the blood levels of dofetilide. High blood levels of dofetilide can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening. You may be more susceptible if you have a heart condition called congenital long QT syndrome, other cardiac diseases, conduction abnormalities, or electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting). Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with dofetilide. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

CONTRAINDICATED: Coadministration with inhibitors of organic cation transporter 2 (OCT-2) may increase the plasma concentrations of dofetilide, which is primarily eliminated by glomerular filtration and active tubular secretion via OCT-2, with minor contribution from CYP450 3A4-mediated metabolism. In 20 healthy male subjects given a 500 mcg oral dose of dofetilide on day 2 of treatment with cimetidine (an OCT-2 and weak CYP450 3A4 inhibitor) 100 mg or 400 mg twice daily for 4 days, dofetilide peak plasma concentration (Cmax) increased by 11% and 29%, respectively, while systemic exposure (AUC) increased by 11% and 48%, respectively, compared to dofetilide plus placebo. Renal clearance of dofetilide decreased by 13% and 33%, respectively, and nonrenal clearance decreased by 5% and 21%, respectively. In addition, the mean maximum change in QTc interval from baseline increased by 22% and 33%, respectively. In another study with 24 healthy volunteers, coadministration of dofetilide 500 mcg twice daily with cimetidine 400 mg twice daily for 7 days increased Cmax and AUC of dofetilide by 50% and 58%, respectively. However, QTc interval was not significantly altered compared to dofetilide alone. In a similar study with 12 healthy male volunteers, dofetilide 500 mcg twice daily given with verapamil (an OCT-2 and moderate CYP450 3A4 inhibitor) 80 mg three times daily for 3 days resulted in a 43% increase in Cmax and 26% increase in AUC (0 to 4 hours) of dofetilide, which corresponded to a 6 msec increase in mean maximum change in QTc from baseline relative to dofetilide alone. In an analysis of patient data from the dofetilide clinical development program, concomitant administration with verapamil was also found to be associated with a higher occurrence of torsade de pointes according to the manufacturer. Dofetilide 500 mcg twice daily given with ketoconazole (an OCT-2 and potent CYP450 3A4 inhibitor) 400 mg daily for 7 days increased dofetilide Cmax and AUC by 53% and 41% respectively, in males, and 97% and 69%, respectively, in females. The same dosage of dofetilide coadministered with trimethoprim (an OCT-2 inhibitor) 160 mg and sulfamethoxazole 800 mg twice daily for 4 days increased dofetilide Cmax by 93% and AUC by 103%.

MANAGEMENT: Given the risk of concentration-dependent QT prolongation, concomitant use of dofetilide with OCT-2 inhibitors is considered contraindicated.

References
  • "Product Information. Tikosyn (dofetilide)" Pfizer US Pharmaceuticals, Atlanta, GA.
  • Johnson BF, Cheng SL, Venitz J "Transient kinetic and dynamic interactions between verapamil and dofetilide, a class III antiarrhythmic." J Clin Pharmacol 41 (2001): 1248-56
  • Abel S, Nichols DJ, Brearley CJ, Eve MD "Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide." Br J Clin Pharmacol 49 (2000): 64-71
Dofetilide

Generic Name: dofetilide

Brand name: Tikosyn

Synonyms: n.a.

Verelan PM

Generic Name: verapamil

Brand name: Verelan PM, Calan, Calan SR, Isoptin SR, Verelan, Isoptin, Isoptin IV, Covera-HS

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction